Clinical pharmacokinetics of irinotecan and its metabolites: A population analysis

Journal of Clinical Oncology

Volumn 20, Issue 15, 2002, Pages 3293-3301

  Xie, Rujia ^a   Mathijssen, Ron H J ^a   Sparreboom, Alex ^a   Verweij, Jaap ^a   Karlsson, Mats O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CARBOXYLIC ACID DERIVATIVE; DRUG METABOLITE; IRINOTECAN; LACTONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; CANCER; CANCER PATIENT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; HYDROLYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CHI-SQUARE DISTRIBUTION; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; TISSUE DISTRIBUTION;

EID: 0036682327     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.073     Document Type: Article

References (28)

1. Irinotecan: A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer
2. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
3. Identification and kinetics of a betaglucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan
4. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes
5. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
6. Identification of a new metabolite of CPT-11 (irinotecan): Pharmacological properties and activation to SN-38
7. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
8. Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
9. Clinical pharmacokinetics of irinotecan
10. Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors
11. Clinical pharmacology of camptothecins
12. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients
13. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan
14. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
15. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection
16. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects
17. Xpose: An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
18. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
19. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues
20. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients
21. CPT-11 converting enzyme from rat serum: Purification and some properties
22. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
23. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes: Differential hydrolysis for the lactone and carboxylate forms
24. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
25. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer: Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer
26. Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors
27. Factors involved in prolongation of the terminal disposition phase of SN-38: Clinical and experimental studies